Ashwin Kishtagari

8PUBLICATIONS
101CO-AUTHORS
Haematological tumoursGene and molecular therapyEpigenetics (incl. genome methylation and epigenomics)Nanotoxicology, health and safetyGene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 10, 2026
Mutation-specific impairment of TET2 and DNMT3A enzymatic activity predicts clonal hematopoiesis disease risk.

Yash Pershad, Kun Zhao, Joseph C Van Amburg

|Apr 16, 2025
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies.

Courtney D DiNardo, Amir T Fathi, Ashwin Kishtagari

|Mar 17, 2025
Genetic drivers and clinical consequences of mosaic chromosomal alterations in 1 million individuals.

Kun Zhao, Yash Pershad, Hannah M Poisner

|Jan 09, 2025
Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants.

Jinsuke Nishino, Wenhuo Hu, Ashwin Kishtagari

|Dec 09, 2024
A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis.

Tamanna Haque, Aditi Shastri, Pinkal Desai

|Jan 15, 2024
Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk.

Ashwin Kishtagari, M A Wasay Khan, Yajing Li

Pageof 2

Frequent Collaborators

5 joint publications

Michael R Savona

4 joint publications

Alexander G Bick

3 joint publications

Alexander J Silver

3 joint publications

Kelly von Beck